Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC [Phase 1, Phase 2]
Clinical trial update for hypofractionated accelerated radiotherapy with concomitant chemotherapy in non-small cell lung cancer (Phase 1/Pha…
-
CLINICAL_TRIALS trial_result · 2019-11-05Clinical Trial Update: Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer [Phase 2, Phase 3]
Phase 2/3 study evaluating chemotherapy in combination with autologous cytokine-induced killer cell immunotherapy for non-small cell lung ca…
-
FDA approval · 2019-11-05FDA Approved: ERLOTINIB — Original Application (Armas Pharmaceuticals Inc.)
The FDA approved Armas Pharmaceuticals' original application (ANDA211960) for erlotinib hydrochloride as a generic version of erlotinib, for…
-
FDA approval · 2019-11-05FDA Approved: ERLOTINIB — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic Erlotinib (ERLOTINIB) under an Original Application (ANDA), providing a generic option f…
-
CLINICAL_TRIALS trial_result · 2019-11-04Clinical Trial Update: Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis [Phase 2]
Phase 2 trial evaluating osimertinib with or without bevacizumab for EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) [Phase 2]
Phase 2 trial update for BELIEF study combining Bevacizumab and Erlotinib in EGFR-mutant non-small cell lung cancer; results posted after co…
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib [Phase 2]
A Phase 2 trial update for TQ-B3139 in ALK-positive non-small cell lung cancer patients who were previously treated with crizotinib; current…
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 clinical trial comparing TQ-B3139 to crizotinib in first-line ALK-positive non-small cell lung cancer is underway but results are no…
-
CLINICAL_TRIALS trial_result · 2019-10-28Clinical Trial Update: Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC [Phase 1]
Phase 1 clinical trial update evaluating TRC105 in combination with paclitaxel/carboplatin and bevacizumab for non-small cell lung cancer ha…
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC [Phase 2]
Phase II study evaluating sorafenib in combination with carboplatin and docetaxel as first-line treatment for advanced non-small cell lung c…
-
CLINICAL_TRIALS trial_result · 2019-10-21Clinical Trial Update: Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC [Phase 1, Phase 2]
Phase 1/2 trial evaluating apatinib in combination with SHR-1210 for non-small-cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2019-10-18Clinical Trial Update: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC [Phase 2]
Phase II study evaluating cabozantinib in RET-positive non-small cell lung cancer is ongoing with an unclear status.
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) [Phase 2]
Phase 2 trial update evaluating first-line combination therapy of sintilimab and anlotinib for advanced non-small cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2019-10-09Clinical Trial Update: A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors [Phase 1, Phase 2]
A phase 1/2 study evaluating PLX3397 in combination with pembrolizumab in advanced melanoma and other solid tumors was terminated; results w…
-
CLINICAL_TRIALS trial_result · 2019-10-07Clinical Trial Update: Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) [Phase 1]
Phase 1 study in Chinese participants with non-small cell lung cancer evaluating safety, tolerability, pharmacokinetics, and efficacy of pem…
-
FDA approval · 2019-10-06FDA Approved: MEKINIST — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for MEKINIST (trametinib) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2019-10-03FDA Approved: GEMCITABINE HYDROCHLORIDE — Supplemental Application (Gland Pharma Limited)
The FDA approved a supplemental application for gemcitabine hydrochloride from Gland Pharma Limited. This approval enables the marketing of …
-
CLINICAL_TRIALS trial_result · 2019-10-03Clinical Trial Update: Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating paclitaxel, carboplatin, and PF-05212384 in advanced or metastatic non-small cell lung cancer has been…
-
CLINICAL_TRIALS trial_result · 2019-10-01Clinical Trial Update: Afatinib in NSCLC With HER2 Mutation [Phase 2]
This update reports results from a Phase 2 trial of afatinib in non-small cell lung cancer patients with HER2 mutations. The study has compl…
-
CLINICAL_TRIALS trial_result · 2019-10-01Clinical Trial Update: A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer [Phase 2]
Phase 2 study evaluating sequential anlotinib followed by EP regimen with concurrent radiotherapy for unresectable stage III non-small cell …
-
CLINICAL_TRIALS trial_result · 2019-09-27Clinical Trial Update: A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC [Phase 2]
Phase 2 trial investigating SHR-1210 with carboplatin and paclitaxel-albumin in resectable non-small cell lung cancer; status is currently u…
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC [Phase 2]
Phase 2 clinical trial evaluating SBRT with sintilimab and GM-CSF for advanced non-small cell lung cancer (Stage IV).
-
CLINICAL_TRIALS trial_result · 2019-09-24Clinical Trial Update: A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 2]
A Phase 2 trial evaluating lurbinectedin alone or with gemcitabine versus docetaxel in second-line non-small cell lung cancer has completed …
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy [Phase 2]
Phase 2 trial update on refining adjuvant therapy for early-stage non-small cell lung cancer (completed).
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer [Phase 2]
Phase 2 trial investigating lisinopril to reduce shortness of breath from radiation therapy in patients with lung cancer has completed with …